cvs caremark - Search News

FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

MinnPost · 10h

FTC says Minnesota-based Optum, et al., inflate cancer drug prices 1,000%

Optum RX, CVS Caremark and Express Scripts are marking up drugs that treat cancer and multiple sclerosis by more than 1,000-percent.

The Financial Times · 1d

FTC says pharmacy benefits managers marked-up generic drug prices for $7.3bn gain

Regulator’s report finds companies ‘hiked costs’ for a range of medicines, including cancer and HIV treatments

Business Insider · 1d

FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on

penncapital-star14m

Regulator accuses drug middlemen of wild price hikes, possibly steering business to themselves

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

Hosted on MSN12h

FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

Healthcare Dive7d

CVS successfully converts commercial pharmacy contracts to “cost plus” model

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

money.rediff8d

Zydus Lifesciences Partners with CVS Caremark for Diabetes Drugs

Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...

11hon MSN

UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

Zacks.com on MSN13h

FTC Report Reveals PBM Practices Impacting Competition and Drug Costs

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics